Med-tech companies seeing for capital will have to work harder this year to attract investor attention. Even though investment firms have money to deploy, the capital will go toward more tarobtained opportunities and later-stage companies. For early stage med tech, 2026 is expected to be a tough year, which is raising concerns about the pipeline of innovative technologies in the long term.
Leave a Reply